Dr Reddy's announces commercial launch of DRDO's anti-COVID-19 drug 2DG
By MYBRANDBOOK
Hyderabad-based Dr Reddy’s Laboratory announced the commercial launch of the anti-Covid-19 drug, 2-Deoxy-D-Glucose (2-DG) for hospitalized moderate to severe Covid-19 patients.
The anti-Covid therapeutic application of 2-DG has been jointly developed by the Institute of Nuclear Medicine and Allied Sciences (INMAS), Defence Research and Development Organisation (DRDO), and Dr Reddy’s Laboratories.
The drug will be supplied to both Government and private Covid-19 health facilities across India. “ The drugs initially will be available at hospitals across metros and Tier 1 cities and in later course expand coverage to rest of the nation, said a company statement and the maximum selling price has been capped at ₹990, with a discounted rate offered to government institutions, it said.
The government institutions will receive at a subsidized rate. Satish Reddy, Chairman, Dr. Reddy’s in the official statement said that 2-DG is another addition to the company’s existing COVID-19 treatment portfolio for mild to moderate and severe conditions and includes a vaccine.
Dr Reddy’s has signed an agreement to distribute Russia’s Covid-19 vaccine Sputnik V in partnership with Snowman Logistics. The Defense Minister, Rajnath Singh had earlier announced that he would personally honour the scientists who played a critical role in the development of the drug as they deserve credit for this achievement.
As per the sources, 2-DG, made of the generic molecule along with an analogue of glucose, accumulates in the virus-infected cells of the body and prevents the invasion of the virus from one cell to another. Viral synthesis and energy production of the virus is cut short stopping it to grow faster helping Covid patients to no longer depend on supplemental oxygen and recover faster.
Initial trials for the drug were conducted between May and October last year at 110 patients at six hospitals. The final phase of the clinical trials was concluded in March 2021 on 220 patients at 27 Covid hospitals. The data from the 2-DG trials suggested the drug usage was safe and Covid-19 patients showed significant recovery.
Nazara and ONDC set to transform in-game monetization with ‘
Nazara Technologies has teamed up with the Open Network for Digital Comme...
Jio Platforms and NICSI to offer cloud services to government
In a collaborative initiative, the National Informatics Centre Services In...
BSNL awards ₹5,000 Cr Project to RVNL-Led Consortium
A syndicate led by Rail Vikas Nigam Limited (abbreviated as RVNL), along wi...
Pinterest tracks users without consent, alleges complaint
A recent complaint alleges that Pinterest, the popular image-sharing platf...
SECUREYE SERVICES PVT. LTD.
BHARAT ELECTRONICS LTD.
ZOHO CORPORATION PVT. LTD.
BPE INDIA PVT. LTD.
ICONS OF INDIA : ROSHNI NADAR MALHOTRA
Roshni Nadar Malhotra is the Chairperson of HCLTech, a leading global ...
ICONS OF INDIA : SANDIP PATEL
Sandip Patel is the Managing Director for IBM India & South Asia regio...
ICONS OF INDIA : SOM SATSANGI
With more than three decades in the IT Sector, Som is responsible for ...
CERT-IN - Indian Computer Emergency Response Team
CERT-In is a national nodal agency for responding to computer security...
ITI - ITI Limited
ITI Limited is a leading provider of telecommunications equipment, sol...
LIC - Life Insurance Corporation of India
LIC is the largest state-owned life insurance company in India...
Indian Tech Talent Excelling The Tech World - NEAL MOHAN, CEO - Youtube
Neal Mohan, the CEO of YouTube, has a bold vision for the platform’s...
Indian Tech Talent Excelling The Tech World - Aneel Bhusri, CEO, Workday
Aneel Bhusri, Co-Founder and Executive Chair at Workday, has been a le...
Indian Tech Talent Excelling The Tech World - Anirudh Devgan , President, Cadence Design
Anirudh Devgan, the Global President and CEO of Cadence Design Systems...